3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
4
Genitourinary
3
Head & Neck
2
Gynecologic
2
Gastrointestinal
2
Endocrine
2
CNS
2
Breast
2
Thoracic
1
NET
1
Lymphoid
1
Dermatologic
1
Conditions
Hematologic Neoplasms
3
Pancreatic Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Melanoma
2
Lymphoproliferative Disorders
2
Breast Neoplasms
2
Brain Neoplasms
2
Thyroid Cancer, Papillary
1
Thrombocytosis
1
Sarcoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Interventions
Magnetic Resonance Spectroscopy
6
Cyclophosphamide
6
X-Rays
5
Phantoms, Imaging
5
Filgrastim
5
pembrolizumab
4
Specimen Handling
4
Radiotherapy
4
Nuclear Medicine Department, Hospital
4
Gemcitabine
4
Biopsy
4
tazemetostat
3
Surveys and Questionnaires
3
Psychiatric Rehabilitation
3
Etoposide
3
Drug Therapy
3
Carboplatin
3
Busulfan
3
Bevacizumab
3
ulixertinib
2
tipifarnib
2
spartalizumab
2
selpercatinib
2
palbociclib
2
olaparib
2
larotrectinib
2
ivosidenib
2
ganitumab
2
ensartinib
2
aflibercept
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
entrectinib
×
Lymphoid
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA